...
首页> 外文期刊>Tierarztliche Praxis, Ausgabe K. Kleintiere >In vivo-efficacy of an ear medication using gelatin powder as a vehicle for the therapy of canine otitis externa
【24h】

In vivo-efficacy of an ear medication using gelatin powder as a vehicle for the therapy of canine otitis externa

机译:使用明胶粉作为犬耳炎的载体的耳药用药的体内疗效

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: Otitis externa is normally treated with daily topical medication. Longer application intervals may be useful to facilitate therapy. In this study, the in vivo efficacy of a gel preparation containing marbofloxacin, dexamethasone and enilconazole was compared to that of a commercial otologic agent containing marbofloxacin, dexamethasone and clotrimazole based on clinical signs, ear cytology and bacterial/fungal cultures. Material and methods: A gel preparation (group A) or a registered otologic agent (group B), respectively, was applied to 41 dogs. A total of 50 ears (25 per group) were analysed. The gel preparation was administered on days 0 and 5; the combination preparation was administered daily according to the manufacturer's recommendations. Dogs were reevaluated clinically and cytologically after 5 and 10 days. Initially and after 10 days, ear swabs were taken for bacterial and fungal cultures. Results: No significant clinical or cytological differences were found between the groups. Significantly more isolates resistant to marbofloxacin were identified in group A after 10 days, although >98% of marbofloxacin was still detectable in vitro after 15 days. Conclusion:The clinical and cytological efficacy of a gel containing defined active agents applied twice 5 days apart was comparable to that of an authorised otologic agent applied once daily. There appears to be an increased risk with the gel in that a resistance to fluoroquinolones develops. Local adverse effects are also possible. Clinical relevance: A gelatine preparation containing active agents may be an alternative to daily topical therapy of canine otitis externa. The development of resistances is possible.
机译:目的:耳炎通常用日常局部用药治疗。更长的应用间隔可用于促进治疗。在该研究中,将含有马巴氟沙星,地塞米松和烯醇酰唑的凝胶制剂的体内疗效与含马巴氟沙星,地塞米松和克拉甲唑的商业耳科,基于临床症状,耳细胞学和细菌/真菌培养物。材料和方法:将凝胶制剂(A)或注册的耳科剂(B)分别施加至41只狗。分析了总共50只耳朵(每组25个)。凝胶制剂在第0天和第5天施用;根据制造商的建议,每天施用组合制剂。狗在5至10天后临床和细胞学上重新评估。最初和10天后,针对细菌和真菌培养服用耳拭子。结果:在组之间没有发现显着的临床或细胞学差异。在10天后,在A组中鉴定出对马巴氟沙星的抗性的耐受抗性的分离物,但在15天后仍然可以在体外检测到98%的马巴氟沙星。结论:含有定义的活性剂的凝胶的临床和细胞学疗效分别施加两次,与每日施用一次施用的耳科剂相当。凝胶的风险似乎是对氟代喹啉的抗性发展的增加。局部不利影响也是可能的。临床相关性:含有活性剂的明胶制剂可以是犬耳炎的日常局部治疗的替代。电阻的发展是可能的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号